Clinical Trial Update: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 study of BCX9930 in Paroxysmal nocturnal hemoglobinuria patients with inadequate response to C5 inhibitors has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCX9930 (Factor D inhibitor)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: TERMINATED | Results posted: 2025-03-07